APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy

Jeffrey B. Kopp, George W. Nelson, Karmini Sampath, Randall C. Johnson, Giulio Genovese, Ping An, David Friedman, William Briggs, Richard Dart, Stephen Korbet, Michele H. Mokrzycki, Paul L. Kimmel, Sophie Limou, Tejinder S. Ahuja, Jeffrey S. Berns, Justyna Fryc, Eric E. Simon, Michael C. Smith, Howard Trachtman, Donna M. MichelJeffrey R. Schelling, David Vlahov, Martin Pollak, Cheryl A. Winkler

Research output: Contribution to journalArticle

401 Citations (Scopus)

Abstract

Trypanolytic variants in APOL1, which encodes apolipoprotein L1, associate with kidney disease in African Americans, but whether APOL1-associated glomerular disease has a distinct clinical phenotype is unknown. Here we determined APOL1 genotypes for 271 African American cases, 168 European American cases, and 939 control subjects. In a recessive model, APOL1 variants conferred seventeen-fold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-ninefold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN). FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects. Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN. The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%. A survey of world populations indicated that the APOL1 kidney risk alleles are present only on African chromosomes. In summary, African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, and APOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly. These data add to the evidence base required to determine whether genetic testing for APOL1 has a use in clinical practice.

Original languageEnglish (US)
Pages (from-to)2129-2137
Number of pages9
JournalJournal of the American Society of Nephrology
Volume22
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

AIDS-Associated Nephropathy
Focal Segmental Glomerulosclerosis
Alleles
African Americans
Chronic Kidney Failure
Apolipoproteins
Kidney Diseases
Genetic Testing
Age of Onset
Chromosomes
Steroids
Genotype
HIV
Phenotype
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Kopp, J. B., Nelson, G. W., Sampath, K., Johnson, R. C., Genovese, G., An, P., ... Winkler, C. A. (2011). APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. Journal of the American Society of Nephrology, 22(11), 2129-2137. https://doi.org/10.1681/ASN.2011040388

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. / Kopp, Jeffrey B.; Nelson, George W.; Sampath, Karmini; Johnson, Randall C.; Genovese, Giulio; An, Ping; Friedman, David; Briggs, William; Dart, Richard; Korbet, Stephen; Mokrzycki, Michele H.; Kimmel, Paul L.; Limou, Sophie; Ahuja, Tejinder S.; Berns, Jeffrey S.; Fryc, Justyna; Simon, Eric E.; Smith, Michael C.; Trachtman, Howard; Michel, Donna M.; Schelling, Jeffrey R.; Vlahov, David; Pollak, Martin; Winkler, Cheryl A.

In: Journal of the American Society of Nephrology, Vol. 22, No. 11, 11.2011, p. 2129-2137.

Research output: Contribution to journalArticle

Kopp, JB, Nelson, GW, Sampath, K, Johnson, RC, Genovese, G, An, P, Friedman, D, Briggs, W, Dart, R, Korbet, S, Mokrzycki, MH, Kimmel, PL, Limou, S, Ahuja, TS, Berns, JS, Fryc, J, Simon, EE, Smith, MC, Trachtman, H, Michel, DM, Schelling, JR, Vlahov, D, Pollak, M & Winkler, CA 2011, 'APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy', Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2129-2137. https://doi.org/10.1681/ASN.2011040388
Kopp, Jeffrey B. ; Nelson, George W. ; Sampath, Karmini ; Johnson, Randall C. ; Genovese, Giulio ; An, Ping ; Friedman, David ; Briggs, William ; Dart, Richard ; Korbet, Stephen ; Mokrzycki, Michele H. ; Kimmel, Paul L. ; Limou, Sophie ; Ahuja, Tejinder S. ; Berns, Jeffrey S. ; Fryc, Justyna ; Simon, Eric E. ; Smith, Michael C. ; Trachtman, Howard ; Michel, Donna M. ; Schelling, Jeffrey R. ; Vlahov, David ; Pollak, Martin ; Winkler, Cheryl A. / APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. In: Journal of the American Society of Nephrology. 2011 ; Vol. 22, No. 11. pp. 2129-2137.
@article{4ee95037a42648eea2b52cd2c23daba5,
title = "APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy",
abstract = "Trypanolytic variants in APOL1, which encodes apolipoprotein L1, associate with kidney disease in African Americans, but whether APOL1-associated glomerular disease has a distinct clinical phenotype is unknown. Here we determined APOL1 genotypes for 271 African American cases, 168 European American cases, and 939 control subjects. In a recessive model, APOL1 variants conferred seventeen-fold higher odds (95{\%} CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-ninefold higher odds (95{\%} CI 13 to 68) for HIV-associated nephropathy (HIVAN). FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects. Individuals with two APOL1 risk alleles have an estimated 4{\%} lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50{\%} risk for developing HIVAN. The effect of carrying two APOL1 risk alleles explains 18{\%} of FSGS and 35{\%} of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67{\%}. A survey of world populations indicated that the APOL1 kidney risk alleles are present only on African chromosomes. In summary, African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, and APOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly. These data add to the evidence base required to determine whether genetic testing for APOL1 has a use in clinical practice.",
author = "Kopp, {Jeffrey B.} and Nelson, {George W.} and Karmini Sampath and Johnson, {Randall C.} and Giulio Genovese and Ping An and David Friedman and William Briggs and Richard Dart and Stephen Korbet and Mokrzycki, {Michele H.} and Kimmel, {Paul L.} and Sophie Limou and Ahuja, {Tejinder S.} and Berns, {Jeffrey S.} and Justyna Fryc and Simon, {Eric E.} and Smith, {Michael C.} and Howard Trachtman and Michel, {Donna M.} and Schelling, {Jeffrey R.} and David Vlahov and Martin Pollak and Winkler, {Cheryl A.}",
year = "2011",
month = "11",
doi = "10.1681/ASN.2011040388",
language = "English (US)",
volume = "22",
pages = "2129--2137",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy

AU - Kopp, Jeffrey B.

AU - Nelson, George W.

AU - Sampath, Karmini

AU - Johnson, Randall C.

AU - Genovese, Giulio

AU - An, Ping

AU - Friedman, David

AU - Briggs, William

AU - Dart, Richard

AU - Korbet, Stephen

AU - Mokrzycki, Michele H.

AU - Kimmel, Paul L.

AU - Limou, Sophie

AU - Ahuja, Tejinder S.

AU - Berns, Jeffrey S.

AU - Fryc, Justyna

AU - Simon, Eric E.

AU - Smith, Michael C.

AU - Trachtman, Howard

AU - Michel, Donna M.

AU - Schelling, Jeffrey R.

AU - Vlahov, David

AU - Pollak, Martin

AU - Winkler, Cheryl A.

PY - 2011/11

Y1 - 2011/11

N2 - Trypanolytic variants in APOL1, which encodes apolipoprotein L1, associate with kidney disease in African Americans, but whether APOL1-associated glomerular disease has a distinct clinical phenotype is unknown. Here we determined APOL1 genotypes for 271 African American cases, 168 European American cases, and 939 control subjects. In a recessive model, APOL1 variants conferred seventeen-fold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-ninefold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN). FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects. Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN. The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%. A survey of world populations indicated that the APOL1 kidney risk alleles are present only on African chromosomes. In summary, African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, and APOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly. These data add to the evidence base required to determine whether genetic testing for APOL1 has a use in clinical practice.

AB - Trypanolytic variants in APOL1, which encodes apolipoprotein L1, associate with kidney disease in African Americans, but whether APOL1-associated glomerular disease has a distinct clinical phenotype is unknown. Here we determined APOL1 genotypes for 271 African American cases, 168 European American cases, and 939 control subjects. In a recessive model, APOL1 variants conferred seventeen-fold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-ninefold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN). FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects. Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN. The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%. A survey of world populations indicated that the APOL1 kidney risk alleles are present only on African chromosomes. In summary, African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, and APOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly. These data add to the evidence base required to determine whether genetic testing for APOL1 has a use in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=80555136780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555136780&partnerID=8YFLogxK

U2 - 10.1681/ASN.2011040388

DO - 10.1681/ASN.2011040388

M3 - Article

C2 - 21997394

AN - SCOPUS:80555136780

VL - 22

SP - 2129

EP - 2137

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 11

ER -